Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Para-Methoxyamphetamine SCHEMBL895775 | 1.00 | SLC6A4 (1.00) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| Para-Methoxyamphetamine SCHEMBL264634 | 1.00 | SLC6A4 (1.00) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| Para-Methoxyamphetamine SCHEMBL7253563 | 0.98 | SLC6A4 (0.96) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| Para-Methoxyamphetamine SCHEMBL10975159 | 0.98 | SLC6A4 (0.96) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL9468376 | 0.94 | SLC6A4 (0.89) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL9468512 | 0.94 | SLC6A4 (0.89) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL6540600 | 0.86 | SLC6A4 (0.74) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL7528408 | 0.84 | SLC6A4 (0.73) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL656814 | 0.84 | SLC6A4 (0.73) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL10774940 | 0.84 | SLC6A4 (0.73) | SLC6A4TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 581 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101983-A1 | NON-STEROIDAL ISONITRILE BINDING COMPOUNDS OF CYTOCHROME P450 SUBTYPES | BRANDEIS UNIVERSITY (US) | 2025-05-15 | — | — | WO | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| CN-117904097-A | Self-assembled protein scaffold co-immobilized enzyme and application thereof | 浙江工业大学 | 2024-04-19 | — | — | CN | claimed |
| CN-115656376-A | Method for separating and detecting formoterol related substances | 苏州易合医药有限公司 | 2023-01-31 | — | — | CN | claimed |
| EP-4061359-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | Turtle Bear Holdings, LLC (US) | 2022-09-28 | — | — | EP | claimed |
| CN-112174837-B | Method for synthesizing (R) -4-methoxy-alpha-methylphenethylamine | 暨明医药科技（苏州）有限公司 | 2022-04-01 | — | — | CN | claimed |
| WO-2021101926-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | STAMETS PAUL EDWARD (US) | 2021-05-27 | — | — | WO | claimed |
| US-20210145851-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS, LLC | 2021-05-20 | — | — | US | claimed |
| US-20210069170-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS, LLC | 2021-03-11 | — | — | US | claimed |
| CN-112174837-A | Method for synthesizing (R) -4-methoxy-alpha-methylphenethylamine | 暨明医药科技（苏州）有限公司 | 2021-01-05 | — | — | CN | claimed |
| EP-1704140-A1 | SYNTHESIS OF OPTICALLY PURE (R)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULPHONAMIDE | LEK Pharmaceuticals D.D. (SI) | 2006-09-27 | — | — | EP | claimed |
| WO-2006070285-A2 | ENZYMATIC PREPARATION OF AN INTERMEDIATE COMPOUND FOR THE SYNTHESIS OF TAMSULOSIN | QUIMICA SINTETICA, S.A. (ES) | 2006-07-06 | — | — | WO | claimed |
| US-20060148046-A1 | Enzymatic process for the preparation of an intermediate compound and use thereof for the synthesis of tamsulosin hydrochloride | QUIMICA SINTETICA, S.A. | 2006-07-06 | — | — | US | claimed |
| WO-2005063701-A1 | SYNTHESIS OF OPTICALLY PURE (R)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULPHONAMIDE | LEK PHARMACEUTICALS D.D. (CH) | 2005-07-14 | — | — | WO | claimed |
| US-20050032781-A1 | Methods for administering active agents to CYP 2D6 sensitive patients | ALKERMES, INC. | 2005-02-10 | — | — | US | claimed |
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | claimed |
| US-20040224960-A1 | Pharmaceutical compositions and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-11-11 | — | — | US | claimed |
| US-20030144220-A1 | Use of CYP2D6 inhibitors in combination therapies | PFIZER INC. | 2003-07-31 | — | — | US | claimed |
| EP-1242058-A1 | USE OF CYP2D6 INHIBITORS IN COMBINATION THERAPIES | Pfizer Products Inc. (US) | 2002-09-25 | — | — | EP | claimed |
| WO-2000059486-A2 | USE OF CYP2D6 INHIBITORS IN COMBINATION THERAPIES | PFIZER PRODUCTS INC. (US) | 2000-10-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | SLC6A4 2641/4885CYP1A2 1124/4885CYP2D6 1338/4885 |
| US-20210145851-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | SLC6A4 62/4885CYP1A2 2048/4885CYP2D6 1702/4885 |
| US-20040224960-A1 | Pharmaceutical compositions and methods for their use | CYP3A5, CYP3A7, CYP3A43 | SLC6A4 1343/4885CYP1A2 5/4885CYP2D6 9/4885 |
| US-20210069170-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | SLC6A4 62/4885CYP1A2 2048/4885CYP2D6 1702/4885 |
| US-20030144220-A1 | Use of CYP2D6 inhibitors in combination therapies | CYP2D6, CYP2B6, CYP3A43 | SLC6A4 433/4885CYP1A2 5/4885CYP2D6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.